Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis

Gastroenterology. 2023 Aug;165(2):492-495.e2. doi: 10.1053/j.gastro.2023.03.230. Epub 2023 Apr 7.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Colitis, Ulcerative* / diagnosis
  • Colitis, Ulcerative* / drug therapy
  • Humans
  • Interleukin-2 / adverse effects
  • Mesalamine / therapeutic use

Substances

  • Interleukin-2
  • Mesalamine
  • Anti-Inflammatory Agents, Non-Steroidal